VR Logo

Myriad Genetics Inc. (MYGN) download report


Healthcare | Diagnostics Services

Myriad Genetics Inc. (MYGN) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally.

IPO Date: 05-Oct-1995

CEO, Pres & Director: Mr. Paul J. Diaz

Exec. VP, CFO & Treasurer: Mr. R. Bryan Riggsbee

Listing: NASDAQ: MYGN

Country: United States

Headquarters: Salt Lake City, UT

Website: https://myriad.com

Key Facts

Market cap: $2,230.20 Mln

Revenue (TTM): $682.40 Mln

Earnings (TTM): $-8.20 Mln

Cash: $268.40 Mln

Total Debt: $89.90 Mln

Insider's Holding: 2.10%

Liquidity: Low

52 Week range: $16.02 - 36.95

Shares outstanding: 80,343,200

10 Years Aggregate:

  • CFO: $982.58 Mln
  • EBITDA: $1,066.55 Mln
  • Net Profit: $406.66 Mln

Stock Performance

Time Period Myriad Genetics (MYGN) S&P BSE Sensex* S&P Small-Cap 600*
YTD-6.141.03-12.41
1 month31.778.637.33
3 months20.547.331.57
1 Year-24.808.43-9.48
3 Years-17.3417.069.22
5 Years0.2812.777.59
10 Years0.3612.8310.53
As on 09-Aug-2022 *As on 08-Aug-2022
Year Myriad Genetics (MYGN) S&P Small-Cap 600 S&P BSE Sensex
202139.5725.2721.99
2020-27.389.5715.75
2019-6.3320.8614.38
2018-15.28-9.705.87
2017106.0311.7327.91
2016-61.3824.741.95
201526.72-3.36-5.03